CareDx Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Total Revenue: Increased 52% to $132 million.

Testing Services Revenue: Up 61% to $100 million, with a testing volume of 58,000 tests (up 17%).

Non-GAAP Gross Margin: Improved to 74%.

Adjusted EBITDA: Increased to $25 million, representing 19% of revenue.

Net Income: GAAP net income of $111 million, or $2.15 per basic share.

Cash Position: Ended the quarter with $374 million in cash and no debt.

Share Repurchase: 570,000 shares repurchased for $12.2 million.

2Strategic Updates and Business Highlights

CareDx has completed its transformation into a precision medicine diagnostics company, focusing on transplantation, specialty oncology, and cell therapy.

Pipeline Progress:

AlloHeme: A recurrence monitoring test for AML and MDS is on track for a 2027 launch, with promising clinical validation results.

HistoMap Kidney: Aims to enhance biopsy assessments and is expected to launch in clinical studies this year.

NavDx Acquisition: Integration is progressing well, with a focus on leveraging CareDx's commercial capabilities and operational scale to drive growth in specialty oncology.

Molecular Testing Adoption: Continued growth in the use of molecular testing in solid organ transplantation, with significant data supporting its role in clinical decision-making.

3Forward Guidance and Outlook

2026 Revenue Guidance: Raised to $490 million - $500 million, reflecting a 30% year-over-year increase.

Adjusted EBITDA Guidance: Updated to $66 million - $78 million.

Testing Volume Projections: Expected to be between 258,000 and 266,000 tests for the year, with Q3 guidance of 72,600 tests and Q4 of 76,300 tests.

4Bad News, Challenges, or Points of Concern

Integration Risks: Ongoing integration of NavDx may pose operational challenges and require significant resources.

Market Competition: The competitive landscape in molecular diagnostics, particularly in oncology, remains a concern as more players enter the market.

Regulatory Environment: While the recent Medicare local coverage determination (LCD) is positive, any future changes in reimbursement policies could impact revenue.

5Notable Q&A Insights

Feedback on LCD: Management indicated that the finalized LCD for AlloSure and AlloMap is expected to support growth, but immediate feedback from clinicians is limited.

Specialty Oncology Volumes: Current guidance reflects a conservative approach, with expectations of 30% growth in specialty oncology volumes as integration progresses.

EBITDA Margin Expansion: There is a commitment to balancing profitability with necessary investments in growth, particularly concerning the integration of NavDx.

Dedicated Sales Team for NavDx: A dedicated sales team is already in place for NavDx products, with plans for expansion to enhance market reach. Overall, CareDx reported strong financial growth and strategic advancements while navigating integration challenges and competitive pressures in the diagnostics market.